Nutzung des menschlichen Peptidoms zur Entwicklung neuer antimikrobieller und anti-Krebs Therapeutika

Das menschliche Peptidom (d.h. die Gesamtheit aller Peptide im menschlichen Körper) umfasst Millionen verschiedener Verbindungen, die zahlreiche physiologische und pathologische Prozesse steuern. Peptide sind insbesondere Schlüsselregulatoren und Effektoren der angeborenen und adaptiven Immunität und modulieren das Überleben und die metastatische Ausbreitung von Krebszellen. Bis heute wurde nur ein kleiner Teil aller endogenen Peptide funktionell charakterisiert. Somit stellt das Peptidom eine kaum erforschte und nahezu unbegrenzte Quelle für die Entdeckung neuer Bioeffektoren dar. Hauptziel des beantragten SFB ist es daher, das menschliche Peptidom zur Entdeckung von Peptiden zu nutzen, die wichtig für die Abwehr und Bekämpfung von Infektionserkrankungen und Krebs sind und diese mittels neuer Technologien für translationale in vivo Anwendungen zu optimieren.

alternative Erklärung

Aktuelles


SARS-CoV-2 Nsp1 blocks protein synthesis and innate immune activation
The novel pandemic Coronavirus SARS-CoV-2 is known to effectively evade human immune defenses. In a close collaboration, the team of Prof. Roland Beckman from the LMU Munich and the labs of Dr. Konstantin Sparrer and Prof. Frank Kirchhoff at the Institute of Molecular Virology, Ulm now revealed the molecular details on how the accessory protein Nsp1 of SARS-CoV-2 shuts down the ribosome and consequently major anti-viral defense systems.

by Dr. Konstantin Sparrer | July 23, 2020


HIV-1 manipulates DNA repair to avoid immune sensing and superinfection
Manipulation of the host cell is essential for replication and spread of HIV-1, the causative agent of AIDS. In a collaborative study, the Wiesmüller and Kirchhoff labs specialized in DNA repair and HIV/AIDS, respectively, now discovered that HIV-1 utilizes its accessory factor Vpu to suppress the accumulation and sensing of nuclear viral DNA species as well as superinfection.

by Prof. Frank Kirchhoff | July 22, 2020


SARS-CoV-2 detected in breast milk

The CRC1279 congratulates Prof. Dr. Jan Münch and his team at the Institute of Molecular Virology Ulm on the first publication of the detection of SARS-CoV-2 in human breast milk 1.

by Kristina Hopfensperger | June 19, 2020


Fighting SARS-CoV-2 – Establishing the basis for future therapeutic strategies


Prof. Dr. Frank Kirchhoff and Jun.-Prof. Dr. Daniel Sauter from the Institute of Molecular Virology receive over 900 000 Euro funding from the Federal Ministry of Education and Research (BMBF) for two new SARS-CoV-2 research projects. Congratulations!

by Kristina Hopfensperger | June 12, 2020


CRC 1279 at the 5th German Pharm-Tox Summit

Congratulations to Maximilian Fellermann who received the young researchers award from the Thieme journal ‘Research’ for the ‘Best Short Presentation 2020 in the subject of Toxicology’.

by Kristina Hopfensperger | March 31, 2020


„Fight nCoV“ – gemeinsam für eine Therapie und Impfung gegen SARS-CoV-2

Die Professoren Jan Münch von der Universität Ulm und Thomas Schrader von der Universität Duisburg-Essen beteiligen sich zusammen mit weiteren europäischen Partnern an dem neuen EU-Projekt „Fight nCoV“. Das Ziel der Forschenden ist es, Wirkstoffe gegen das neue Coronavirus zu testen. Einige vielversprechende Kandidaten sind unter anderem die von Profs. Münch und Schrader entwickelten molekularen Pinzetten.

March 26, 2020 | 🔗 schwaebische.de


The essentials of science communication
The relevance of science communication has been steadily increasing during the last years. The CRC1279 invited Dr. Tobias Maier from the National Institute for Science Communication in Karlsruhe to host a workshop in Ulm.

by Kristina Hopfensperger | March 10, 2020


Introducing the new President of the German Society of Experimental and Clinical Pharmacology and Toxicology: Prof. Dr. Holger Barth
The German Society of Experimental and Clinical Pharmacology and Toxicology (DGPT) nominated CRC1279 member Prof. Dr. Holger Barth to be their president for 2020. Prof. Dr. Barth took over the responsibilities from the outgoing president Prof. Dr. Wieland.

by Kristina Hopfensperger | February 10, 2020


International CRC1279 symposium at Lake Federsee

At the 22nd and 23rd of October over 60 CRC1279 members and several international experts joined the international CRC1279 symposium in Bad Buchau next to the beautiful lake Federsee.

by Kristina Hopfensperger | November 25, 2019


Time to say goodbye… and hello Kristina!

Annika Röcker, so far responsible for Public Relations and Event reports of the CRC homepage, will leave us by the end of March 2019. Luckily, Kristina Hopfensperger will take over.

by Dr. Annika Röcker, Kristina Hopfensperger and Prof. Dr. Frank Kirchhoff


Kontakt



SFB Geschäftsstelle
Kristina Wohllaib
Tel.: 0731 500 65152
mail: kristina.wohllaib@uni-ulm.de


Sprecher:
Kirchhoff, Frank, Prof. Dr.
Institute of Molecular Virology
Ulm University Medical Center
Meyerhofstr. 1
89081 Ulm
Tel.: 0731 50065150
mail: frank.kirchhoff@uni-ulm.de

    CRC 1279 Upcoming Events



  • For more information and previous CRC1279 Monday Seminars klick here

Building the CRC1279 Webpage


Kristina Hopfensperger

Public Relations and Content

Kristina Hopfensperger: kristina.hopfensperger@uni-ulm.de
PhD student at the institute of Molecular Virology Ulm


alternative Erklärung

Web Design and Content

Dr. Dré van der Merwe:
dre.van-der-merwe@uni-ulm.de
Lab Manager at the institute of Molecular Virology Ulm


alternative Erklärung

Web Design

Fabian Zech:
fabian.zech@uni-ulm.de
PhD student at the institute of Molecular Virology Ulm